This web only provides the extract of this article. If you want to read the figures and tables, please reference the PDF full text on Blackwell Synergy. Thank you.
- Review -
Physiological and pharmacological basis for the ergogenic
effects of growth hormone in elite sports
Christer Ehrnborg, Thord Rosén
Endocrine Section, Sahlgrenska University Hospital, S-413 45 Göteborg, Sweden
Abstract
Growth Hormone (GH) is an important and powerful metabolic hormone that is secreted in a pulsatile pattern
from cells in the anterior pituitary, influenced by several normal and pathophysiological conditions. Human GH was
first isolated in the 1950s and human derived cadaveric GH was initially used to treat patients with GH deficiency.
However, synthetic recombinant GH has been widely available since the mid-1980s and the advent of this
recombinant GH boosted the abuse of GH as a doping agent. Doping with GH is a well-known problem among elite athletes
and among people training at gyms, but is forbidden for both medical and ethical reasons. It is mainly the anabolic
and, to some extent, the lipolytic effects of GH that is valued by its users. Even though GH's rumour as an effective
ergogenic drug among athletes, the effectiveness of GH as a single doping agent has been questioned during the last
few years. There is a lack of scientific evidence that GH in supraphysiological doses has additional effects on muscle
exercise performance other than those obtained from optimised training and diet itself. However, there might be
synergistic effects if GH is combined with, for example, anabolic steroids, and GH seems to have positive effect on
collagen synthesis. Regardless of whether or not GH doping is effective, there is a need for a reliable test method to
detect GH doping. Several issues have made the development of a method for detecting GH doping complicated but
a method has been presented and used in the Olympics in Athens and Turin. A problem with the method used, is the
short time span (24_36 hours) from the last GH administration during which the test effectively can reveal doping.
Therefore, out-of-competition testing will be crucial. However, work with different approaches to develop an alternative,
reliable test is ongoing. (Asian J Androl 2008 May; 10: 373_383)
Keywords: growth hormone; IGF-I; doping; doping test; athletes; maximum exercise test; supraphysiological; anabolic androgenic steroids;
bone markers
Correspondence to: Dr Thord Rosén, Endocrine Section, Sahlgrenska University Hospital, S-413 45 Göteborg, Sweden.
Tel: ++46-31-342-7055 Fax: +46-31-82-1524
E-mail: thord.rosen@medic.gu.se
Received 2007-12-11 Accepted 2007-12-18
DOI: 10.1111/j.1745-7262.2008.00403.x
1 Introduction
Doping with growth hormone (GH) is a well-known problem in the world of sports and has been known for
decades [1]. GH was described as a potent performance-enhancing anabolic agent in The Underground Steroid
Handbook first published in California in the early 1980s [2].
Its misuse has since increased, especially since the
advent of recombinant GH in the late 1980s. It rapidly gained popularity as it was said to be "efficient, hard to detect and
without major side-effects" and users can currently be found both among elite athletes and among people training at
gyms [3, 4].
It is mainly the anabolic and, to some extent, lipolytic effect of GH that is valued by users since a
reduction in fat mass, especially centrally located fat mass, is a desirable GH effect in a doping situation, especially in body-building
competitions where a minimum of visible body fat is rewarded.
2 Historical background
The existence of a growth-promoting substance in the anterior hypophysis was described in animals in the 1920s
[5]. Human GH was first isolated by Li et
al. [6] in 1956 and, in the early 1970s, the structure of GH was
subsequently shown to consist of a single polypeptide
chain of 191 amino acids with two disulphide bridges and a molecular
weight of 22 kDa [6_8]. It was then stated that 22 kDa
GH is the major isoform of GH but a 20 kDa GH variant
comprises 5%_10% of the pituitary GH and that a number
of other isoforms produced by the pituitary also exist [9,
10]. The gene for GH has been cloned and characterised
and synthetic GH is currently produced in bacteria using
recombinant DNA technology [11].
Children with GH deficiency (GHD) have been treated
with GH since the 1950s, when it was demonstrated that
treatment with human GH, purified from cadaver
pituitaries increased linear growth [12]. The first paper
describing GH treatment in adults was presented in 1962
[13] and described the treatment of a 35-year-old GHD
woman with human GH. The patient noticed "increased
vigour, ambition and sense of well-being" after two
months of treatment [13]. Treatment with GH was
however initially restricted by the limited supply of GH and
also by the recognition of the risk of Creutzfeldt-Jacobs
disease with cadaveric GH, before the advent of widely
available recombinant human GH in the mid-1980s. The
introduction of recombinant GH made it possible to
further study the effects of GH in adults and the
consequences of the clinical entity of GHD, including its
treatment, have been well described [14_17].
3 Physiology of GH secretion
GH is secreted in a pulsatile pattern from somatotrope
cells in the anterior hypophysis, regulated in a complex
pattern by two hypothalamic peptides; a stimulating
hormone, GH releasing hormone (GHRH), and an
inhibiting hormone, somatostatin [18_21].
GH secretion is influenced by several normal and
pathophysiological conditions, such as gender, age, sleep,
physical exercise, nutritional state and other metabolic
factors.
3.1 Gender
A difference between men and women in the GH release at rest, with greater release in young women than
in age-matched men, has been described [22_24].
Gonadal steroids interact with GH and the administration of
oestrogen increases serum levels of GH [25_29]. Testostereone and GnRH treatment in hypogonadal men
has been shown to increase GH secretion [30]. Oestrogens
enhance GH secretion, mainly indirectly by inducing
GH resistance resulting in higher serum levels of GH in
females of reproductive age, a somewhat different
secretion pattern and GH production rate [21, 29].
3.2 Age
It has been estimated that there is a 14% decrease in
GH secretion per decade of adult life, following a peak
during puberty [31].
3.3 Sleep
The GH levels are highest during slow wave sleep
and lowest during rapid eye movement sleep [32].
3.4 Physical exercise
Physical exercise has a stimulatory effect on GH
secretion [33]. The GH levels rise in response to acute
exercise, with a threshold level of approximately 70% of
VO2-max [34], and a twofold rise in GH concentrations
after a year of high-intensity aerobic training has been
shown in subjects who exercised consistently above the
lactate threshold [35].
3.5 Nutritional state and other metabolic factors
Fasting results in enhanced GH production [36], while
it is suppressed by glucose [37] and fatty acids [38].
Certain amino acids such as leucine and arginine enhance
GH secretion [39, 40].
3.6 Hormones
Hyperthyroidism is associated with increased GH
secretion [41], while hypothyroidism is associated with
low GH levels [42]. The net effect of corticoids is
inhibition of the GH secretion [43].
3.7 Neurotransmitters
Both α2-adrenergic agonists and cholinergic agents
stimulate GH secretion [44], the latter probably via
suppression of somatostatin release [45].
4 GH and muscles
GH is an important and powerful metabolic hormone.
An anabolic effect by GH in normal adults was
demonstrated in 1958 by Ikkos et al. [46] who observed a
nitrogen-retention effect after GH administration. Patients
with untreated acromegaly have shown a markedly increased body cell mass estimated from assessments of
total body potassium [47]. The body cell mass in
acromegalic patients decreases in response to surgical
treatment [48]. Furthermore, it has been shown that
acromegaly causes myopathy with hypertrophic, but functionally
weaker muscles [49, 50]. This could indicate that there
are negative effects on muscle function following
exposure to high levels of GH for a long period of time.
GH promotes the positive protein balance in skeletal
muscle by increasing protein synthesis and possibly by
inhibiting protein breakdown [51].
Adult GHD patients have a reduced muscle mass,
isometric muscle strength and functional exercise capacity
compared with healthy controls [52, 53]. Furthermore,
isokinetic muscle strength and local muscle endurance
are reduced or in the lower range [52, 54_56]. The
reduced muscle mass and isometric strength could be an
effect of reduced muscle cross-sectional area in GHD
patients [57], but it could also be caused by a reduction in the
peak torque per muscle area [58], suggesting that
contractile properties and neural activation might be responsible for
the reduction in muscle strength in adult GHD patients.
GH replacement therapy in GHD adults increases lean
body mass (LBM), exercise capacity, muscle volume,
muscle mass and maximum voluntary isometric muscle
strength [15, 52, 55, 59_63]. The changes in muscle
mass and maximum voluntary isometric muscle strength
has been shown to become apparent after approximately
one year of therapy [55]. However, dynamic muscle
strength has not shown any obvious increase in response
to GH treatment [60, 64].
The proportion of fast-twitch, type-2 muscle fibres
is increased in hypophysectomised rats [65]. However,
the histology of muscles from GHD patients does not
appear to differ from that of healthy adults [66] and it
has not been possible to detect any changes in the
proportions of muscle fibres in adult GHD patients
receiving GH treatment [66, 67].
5 Lipolytic effects of GH
The lipolytic effects of GH have been known for
decades. GH-induced lipolysis was first demonstrated
in humans in 1959 [68]. Lipolytic effects have also been
demonstrated in GHD and acromegaly patients. GHD patients have increased total body fat and reduced body
cell mass and extracellular water (ECW) [69, 70]. GH
treatment given to these patients improves the body
composition [17, 54, 71]. Furthermore, patients with
untreated acromegaly have a marked decrease in adipose
tissue mass compared with normal individuals [47] and
surgical treatment results in an increase in the fractions
of adipose tissue in the subcutaneous trunk and the
intra-abdominal depots, while the fractions of adipose tissue
in peripheral depots decrease [48].
Meals inhibit GH release, whereas fasting conditions
amplify the pulsatile pattern of GH secretion [72],
indicating that the main impact of GH is in the fasting
state. Dose-dependent action by GH on the induction of
lipolysis has been demonstrated, with an elevation of
circulatory free fatty acids (FFAs) and glycerol and
increased lipid oxidation rates [73]. These effects occur
despite increased insulin levels, indicating that relatively
low doses of GH can overcome the lipogenic actions of
insulin. GH stimulates lipolysis by activating
hormone-sensitive lipase activity, with a subsequent increase in
lipid oxidation [74].
6 Antinatriuretic effects of GH
A sodium-retention effect with the simultaneous
expansion of ECW after GH administration was demonstrated in 1952 [75]. Even though it is not the main
focus of attention in a doping situation, the
anti-natriuretic effect of GH is still of interest.
The sodium and water-retaining effect of GH is complex. To summarise, both GH and IGF-I are capable
of causing fluid retention by stimulating
Na+K+ATPase activity in the distal nephron [76]. However, the
stimulation of the renin-angiotensin-aldosterone system (RAAS)
[77], the down-regulation of atrial natriuretic peptide (ANP)
[78] and increased endothelial nitric oxide (NO) function
have also been proposed as possible mechanisms [79].
The anti-natriuretic effects of GH explain the
reduction in ECW that is found in adult patients with severe
GHD and the marked increase in ECW found in acromegalic patients [47, 69]. However, the exact mechanisms
behind these effects are unknown. ECW is increased by
as much as 25% in untreated acromegaly patients, an
increase that normalises after successful treatment [80].
After treatment, the excess ECW correlates with the GH
concentrations [80]. Further studies of acromegalic
patients suggest a curve-linear dose-response relationship
between GH concentrations and excess ECW [80, 81].
7 GH effects on bone
GH has a stimulating effect on both osteoblasts and
osteoclasts and is thereby involved in the regulation of
bone metabolism [82_84], leading to both bone
formation and resorption [85, 86]. The osteoclasts,
osteoblasts and components of the bone matrix release
several peptides and proteins into the circulation during bone
resorption and formation: peptides and proteins that can
be used as biochemical markers of bone metabolism.
In adult GHD patients, both normal [87] and reduced
[88] serum levels of biochemical markers of bone
turnover have been shown. Several studies of hypopituitary
patients have shown that GH treatment accelerates bone
turnover [85, 89, 90]. Furthermore, it has been shown
that biochemical markers of bone formation and bone
resorption increase within a few weeks after the
initiation of GH treatment in GHD adult patients [91].
8 GH doping among athletes and in the gyms
GH-doping is mostly seen in sporting disciplines that
favour strength and explosivity, that is among weightlifters,
body builders, football players (American football) and
sprinters, but to some extent also in endurance athletes. It
is also used by some female athletes, who want to avoid
the androgenic side-effects of the AAS. The exact figures
of GH-doping among elite athletes and among people
training in gyms are not known and there is a lack of studies
on the prevalence of GH usage. One study has reported
that 5% of male American high-school students used or
have used GH as an anabolic agent [3]. However, this
study was published in 1992 and whether the results
are valid today is not sure. Furthermore, the figures
in this study are based on self-reports in a survey and
there might be a risk of an overestimation of the usage,
since GH might have been considered as an anabolic
steroid, resulting in a higher prevalence. GH is often
administered 3_10 mg/day, 3_4 times per week when taken alone, and
1_3 mg daily if combined with AAS, thus well above the doses given in cases of adult
GH-deficiency. The administration is usually taken in
cycles that vary from 6_12 weeks to 6_12 months in
length. However, different patterns and doses have
been described.
The fact that most abusers probably use GH in combination with AAS and that this combination
possibly has an anabolic effect, due to synergistic actions
between the two agents, is important to take into
account when discussing GH as a doping agent.
9 Doping with GH
This misuse of GH is forbidden for both medical
and ethical reasons. Several issues have made the
development of a method for detecting GH doping
complicated [92]. It is, for example, not possible to
distinguish exogenous recombinant GH from endogenous
GH in a blood or urine test. Furthermore, GH
secretion is influenced by many different factors such as
exercise, food intake, sleep and stress [23]. A test
method based on the different GH isoforms has been
presented and used in the Olympics in Athens and Turin
[93, 94]. However, there are some disadvantages with
this method. The previous lack of an official method
to discover GH doping, might partly explain the strong
position GH is thought to enjoy as a doping agent in
elite sports.
The GH-2000 project was initiated by the
International Olympic Committee (IOC) with the aim of
developing a method for detecting GH doping among athletes.
The project was funded by the European Union (EU) BioMed2 Research Programme, with
additional support from industry and the IOC.
Prior to the start of the GH-2000 project, Wallace
et al. [95_98] studied the effects of exercise
and supraphysiological GH administration on the GH/IGF-I axis
and bone markers in 17 athletic adult males. To
summarise, acute exercise increased all the molecular
isoforms of GH, with 22 kDa GH constituting the major isoform, with a peak at the end of acute exercise
[95]. The proportion of non-22 kDa isoforms increased after exercise, due in part to the slower
disappearance rates of these isoforms. With
supraphysiological GH administration, these exercised-stimulated
endogenous GH isoforms were suppressed for up to four days [96].
Moreover, all the components of the IGF-I ternary complex transiently increased with acute
exercise and GH pre-treatment augmented these exercise-induced changes [97].
Furthermore, acute exercise increased the serum concentrations of the bone
and collagen markers, bone-specific alkaline
phosphatase, carboxy-terminal cross-linked telopeptide of type
I collagen (ICTP), carboxy-terminal propeptide of type
I procollagen (PICP) and procollagen type III
(P-III-P), while osteocalcin was unchanged. GH treatment
resulted in an augmented response to exercise of the
bone markers PICP and ICTP [98].
A forthcoming method to discover GH abuse will probably necessitate the use of specific markers of
the GH/IGF-I axis and bone markers, with the
prerequisite that these variables are more sensitive to
exogenous GH administration than to exercise. As a result,
it will be important closely to study how the levels of
these variables are influenced by a maximum exercise test
in comparison to rest and by other factors such as gender,
age, fitness, type of sport, medication, menstrual status or
illness. Furthermore, it will be important to closely study
the effects of different types of injuries, for
example fractures, on the specific markers.
10 GH and exercise
Physical training has been shown to change
circulating levels of GH and, more inconsistently, IGF-I in
normal subjects in relation to improvements in oxygen uptake and muscle strength
[99_102].
It is well known that acute exercise above a
certain intensity is one of the most potent stimulators of
GH secretion and the magnitude of the GH response is
closely related to the peak intensity of exercise, rather
than to total work output [33, 34, 103]. Exercise not
only mediates the acute effects on GH secretion. It
has been shown that one year of endurance training
above the lactate threshold, increases the basal 24-h
pulsatile GH release [35]. Interestingly, subjects
training below the lactate level did not show any change in
the GH release, indicating that the training intensity
may be important in regulating the GH-axis as well as
fitness. This physiological GH increase in response
to exercise and to other stimuli such as hypoglycemia
makes it difficult to use measurements of GH itself in
blood as a doping marker, as it would be difficult to
discriminate a high exercise-derived endogenous GH
level from that resulting from exogenous GH.
In addition, bone markers have been shown to respond to exercise and the effects of low-intensity
endurance-type activity or brief high-intensity or
resistance exercise have shown no acute change [104_106],
increased markers [107, 108] or transient decreased
markers [106]. Furthermore, studies of high-intensity exercise
showed no rise in PICP or ICTP in response to exercise
[104, 106, 108]. This could suggest that the duration of
exercise is important in the response by bone markers to
acute exercise.
11 Variability
Acute exercise above a certain intensity is one of the
most potent stimulators of GH secretion. It is well known
that elite athletes are able to train at much higher
intensities than the normal population and that, during a training
season, there are significant differences in training
intensity, which might influence GH secretion. Many of
the GH-related mediators, binding proteins and markers
do not exhibit the same fluctuations as GH and there is a
real lack of knowledge about the seasonal stability of
markers of the GH/IGF-I axis and circulating bone
markers in athletes. A study of seasonal patterns of sleep
stages and secretion of cortisol and GH during 24-hour
periods in northern Norway revealed no difference in
GH secretion as a function of season of the year [109].
Another study reveals no circannual rhythm of plasma
GH in pre-pubescent subjects [110].
There is some evidence that biological rhythms of
bone turnover over long periods, such as circannual
variation, exist [111_118]. Woitge et al. [118] have
shown that seasonal variation contributes to the
biological variability in bone turnover and needs to be taken into
account when interpreting the results of bone marker
measurements.
12 Supraphysiological doses of GH: effects on muscles,
power, exercise capacity and body composition
GH plays a regulatory role in the maintenance of
normal body composition through its well-known anabolic, lipolytic and antinatriuretic actions.
These effects are easily demonstrated when GH-substitution
therapy is initiated in patients with GHD, reversing
muscle atrophy and decreasing central abdominal
adiposity and dry skin, signs typically associated with
GHD [15, 17, 119]. The anabolic actions of GH include
stimulated protein synthesis through the mobilisation of
amino-acid transporters, which is reflected in
vivo by an increase in the metabolic clearance rate of amino acids.
IGF-I also directly stimulates protein synthesis, albeit to a
lesser extent than GH, while insulin inhibits protein
breakdown [120_124].
Even though GH has been regarded as an effective
ergogenic drug among athletes since the 1980s, only
a few controlled studies of the effectiveness of GH in
relation to physical performance and the effects on
body composition in athletes have been performed.
A study of 16 young, healthy adults revealed no
differences between the GH or placebo group in terms of
muscle size, strength or muscle protein synthesis
after GH (40 μg/kg/day) or placebo treatment for 12
weeks combined with heavy-resistance exercise. However, fat free mass (FFM) and total body water
(TBW) increased in both groups but significantly more
among the GH recipients [125]. Another study of 22
power athletes assigned in a double-blind manner to
either GH treatment (30 μg/kg/day) or placebo for a
period of six weeks revealed no difference between
the groups in terms of maximum voluntary strength (biceps or quadriceps) and no change in body weight
or body fat, but a remarkable increase in IGF-I was
noted [126]. Crist et al. [127] found increased fat
free weight and decreased body fat in eight well-trained
adults when given 2.67 mg of GH 3 days/week for six
weeks. A study of healthy, experienced male
weight-lifters before and at the end of 14 days of
subcutaneous GH administration (40 μg/kg/day) revealed no
increase in the rate of muscle protein synthesis or
reduced whole body protein breakdown, metabolic alterations that would promote muscle protein
anabolism [128]. In a placebo-controlled study by Healy
et al. [129] including 11 endurance-trained athletes, who
received supraphysiological GH-doses (67 μg/kg/day)
or placebo during four weeks, it was concluded that
GH had a net anabolic effect on whole body protein
metabolism at rest and during and after exercise. The
whole body protein metabolism was measured with a
1-(13C) leucine method. Although no muscle power
test was performed in the study, it was thus speculated that the acute excess GH administration might
have short-term benefits for physical performance.
Finally, in two studies from our own group, we found
that treatment with supraphysiological doses of GH
during one month given to healthy individuals resulted in a
decrease in body fat, an increase in ECW but no visible
effect in ICW, indicating limited anabolic effect on muscles.
Furthermore, no improvements in power output or
oxygen uptake in a bicycle exercise test before and after
treatment were observed [130, 131].
Some studies performed on elderly men show the same results.
A study of healthy, sedentary men with low serum IGF-I levels who followed a 16-week
progressive resistance-exercise program (75%_90% max
strength, 4 days/week) after random assignment to either a GH
(12.5_24.0 μg/kg/day) or placebo group showed that resistance-exercise training improved
muscle strength and anabolism, but these improvements were not enhanced when exercise was
combined with daily GH administration [132]. Further
supportive findings of the lack of effect are found in
elderly but not particularly GH-deficient men. Taffee
et al. [133, 134] were unable to see any increase in strength,
muscle mass or fibre characteristics after GH
treatment during a resistance-exercise training programme.
There is a discrepancy between GH's rumour as a
strong anabolic agent and the lack of effects seen in
the studies performed. There are some different
explanations to this that might be taken into consideration.
The doses used in the different studies might be too low,
even though being supraphysiological and thought to be
equal to the doses used by GH abusers. Furthermore,
most abusers probably use GH in combination with AAS
and this combination might have an anabolic effect, due to
synergistic actions between the two agents.
The reduction in fat mass, especially centrally
located fat mass, has also been suggested as a desirable
GH effect in a doping situation, especially in
body-building competitions where a minimum of visible body
fat is rewarded.
13 Side-effects of GH
The fear of the well-known side-effects of GH also
reduces its use in the gyms. The fluid retention
symptoms with swollen hands and feet and carpal tunnel
syndroms reduce the exercise performance, thereby
limiting the potential of GH as a powerful doping agent.
Long-term use also increases the risk for ordinary acromegalic symptoms.
Due to high costs of the "clean" rhGH, some athletes use the cheaper
cadaveric GH, with the potential risk of ending up in
fatal Creutzfeldt-Jacobs disease.
14 GH doping: current and future aspects
The use of GH as a doping agent is widespread and doping with GH has become an increasing
problem in sports and among young people at ordinary gyms
during the last 10_15 years [3, 4, 135]. The actual
use of GH as a doping agent is not known, but 5% of
male high-school students in the USA have been reported to have used it [3].
The GH abusers primarily aim to benefit from the potential anabolic effects of
GH, mostly in combination with AAS, in order to increase muscle mass and muscle power.
It has also been popular among female athletes, who wish to avoid
the androgenic side-effects of anabolic steroids.
However, our own interviews with hormone abusers (to be published elsewhere) indicate a more
differentiated pattern of GH doping, revealing that its effect is
preferentially on muscle volume, and not on muscle
strength, thereby making it more popular among
body-builders than among weightlifters.
Although previous reports from GH-abusing athletes uniformly describe the positive effects of GH
doping on muscle volume and strength [135], the effectiveness of GH as a doping agent has been
questioned during the last few years. There is a lack of
scientific evidence that GH in supraphysiological doses
has additional effects on muscle exercise performance
than those obtained from optimized training and diet
itself [125, 126, 128, 134, 136_138]. These data have
initiated speculations that the reputation of GH as an
effective doping agent is highly exaggerated, at least
when taken alone. However, in elite athletes, even a
small increase in muscle power or exercise performance might make the difference between a gold or
silver medal. Furthermore, there is a great deal of
counterfeit, inactive GH present on the black market,
complicating the real picture of the effectiveness of
GH as a doping agent.
There are risks involved with GH abuse. Several
potential risk factors have been suggested by
observations in GH-supplemented and acromegalic patients,
including carpal tunnel syndrome and pitting edema
[139], myocardial hypertrophy, and cancer [140,
141]. Because GH needs to be injected there is also a risk of
hepatitis and HIV if the abusers share syringes. Finally,
cadaver-derived GH is still present on the black
market and abusers using this could acquire the fatal
Creutzfelt-Jacob disease [4, 142].
Taken as a whole, there is no published evidence
of any anabolic effect on muscles or positive effects
on physical performance as a result of GH alone or
combined with exercise [136_138].
It has been claimed that one main function of GH is
its stimulating effect on collagen synthesis and that this
might have positive consequences for athletes [143,
144]. In a review, Doessing and Kjaer [143]
concluded that supraphysiological doses of GH do not appear
to increase the synthesis of myofibrillar protein, but
that it is possible that a supraphysiological GH level
has an effect on connective tissue. It is known that
the GH/IGF-I level is associated with pathological
changes in connective tissue in patients with clinical
conditions involving a change in GH activity
[145_150]. Furthermore, studies of healthy subjects treated with GH
have revealed an increase in levels of whole body collagen
synthesis [98, 151], indicating that there is a stimulatory
effect on connective tissue in normal healthy subjects.
Tendons heal more rapidly in rats treated with GH
[152] and anecdotal reports have suggested that GH
prevents tendon and muscle ruptures, especially if
combined with AAS [153]. By protecting the
myotendinous junction regarded as a "weak link in the
chain" in athletes training at high intensity and in those with
fast-growing muscles due to heavy resistance training
and/or AAS abuse, GH could therefore enable training at
even higher intensity with shorter recovery periods.
15 Test methods
Regardless of the effectiveness of GH, there is a huge
need for the development of a test method to detect GH
doping. The problem of developing a reliable method
has been described in several papers and work on
different approaches is ongoing [2, 92, 154, 155].
15.1 Isoform method
There are currently two main approaches to
developing a method for detecting GH doping. The first is an
isoform method, developed by the Strasburger group,
based on the knowledge that normal, endogenous GH exists in a variety of isoforms. In the pituitary, the most
abundant isoform is 22-kDa GH, but other isoforms
(non-22-kDa GH) are present in varying amounts [156].
Recombinant GH, in contrast, is solely made up of the
22-kDa isoform. Wallace et al. [96] have shown that all the
measured isoforms of GH increased during and peaked
at the end of acute exercise, with 22-kDa GH
constituting the major isoform in serum during exercise. They
also found that the proportion of non-22-kDa isoforms
increased after exercise, due in part to slower
disappearance rates of 20-kDa GH and perhaps other non-22-kDa
GH isoforms. Furthermore, it has been shown that supraphysiological doses of GH in trained adult males
suppressed exercise-stimulated endogenous circulating
isoforms of GH for up to 4 days and that the clearest
separation of treatment groups required the simultaneous
presence of high exogenous 22-kDa GH and suppressed
20-kDa or non-22-kDa GH concentrations [95].
Consequently, even if it is not possible directly to
distinguish exogenous recombinant GH from endogenous
GH in a blood or urine test, the method developed by the
Strasburger group, which was used in the Athens
Summer Olympics (2004) and in the Turin Winter Olympics
(2006), is based on the change in the normal ratio of
22/non-22-kDa GH isoforms after treatment with exogenous
GH. One disadvantage with this isoform-based method,
however, is that it is only able to detect GH up to 24 h
after the last treatment and, therefore,
out-of-competition testing will be crucial.
15.2 GH marker-based method
The other approach to detecting GH misuse is to use
longer-lasting GH-dependent markers. This approach,
used by the GH-2000 group, involves markers that are
more sensitive to exogenous GH substitution than
exercise-induced GH increase. Several papers from GH-2000
have been published [129, 151, 157_160] and the results
from the GH-2000 group have resulted in mathematical,
statistical formulae that have been presented as a
potential test for detecting GH doping [160]. This method has
then been further validated in a study stating that the test
proposed by the GH-2000 study group can be used to
detect subjects receiving exogenous GH [161].
However, some questions still remain before an accurate, reliable method is found. The test proposed
by the GH-2000 study group requires further evaluation
and discussion before it can be finally accepted as a
doping test. Any test to detect drug abuse in sport must
minimize the risk of a false positive result.
16 Conclusion
The role of GH as an effective anabolic muscle
doping agent, when taken alone, is questioned. GH might be
effective, in lower doses, when taken together with AAS.
GH doping does not seem to have any positive effect on
cardiac performance. Fluid retention and other
acromegalic side-effects further reduce its use. However, GH
seems to stimulate collagen synthesis, which might have
a positive, protective effect on ruptures of muscles and
tendons, and allow harder training with a shorter
recovery period, thus explaining its ongoing use in doping areas. It
cannot be excluded that this effect on collagen synthesis
might be useful in a few years in clinical practice for the
treatment of muscle and tendon ruptures.
References
1 Macintyre JG. Growth hormone and athletes. Sports Med 1987;
4: 129_42.
2 Sonksen PH. Insulin, growth hormone and sport. J Endocrinol
2001; 170: 13_25.
3 Rickert VI, Pawlak-Morello C, Sheppard V, Jay MS. Human
growth hormone: a new substance of abuse among adolescents?
Clin Pediatr (Phila) 1992; 31: 723_6.
4 Ehrnborg C, Bengtsson BA, Rosen T. Growth hormone abuse.
Baillieres Best Pract Res Clin Endocrinol Metab 2000; 14: 71_7.
5 Evans HM, Long JA. The effect of the anterior lobe
administered intraperitoneally upon growth maturity, and oestreus cycles
of the rat. Anat Rec 1921; 62_3.
6 Li CH, Papkoff H. Preparation and properties of growth
hormone from human and monkey pituitary glands. Science 1956;
124: 1293_4.
7 Li CH, Dixon JS. Human pituitary growth hormone. 32. The
primary structure of the hormone: revision. Arch Biochem Biophys
1971; 146: 233_6.
8 Niall HD. Revised primary structure for human growth hormone.
Nature New Biol 1971; 230: 90_1.
9 Lewis UJ, Dunn JT, Bonewald LF, Seavey BK, Vanderlaan WP. A
naturally occurring structural variant of human growth hormone.
J Biol Chem 1978; 253: 2679_87.
10 Baumann G, MacCart JG, Amburn K. The molecular nature of
circulating growth hormone in normal and acromegalic man:
evidence for a principal and minor monomeric forms. J Clin
Endocrinol Metab 1983; 5: 946_52.
11 Goeddel DV, Heyneker HL, Hozumi T, Arentzen R, Itakura K, Yansura
DG, et al. Direct expression in Escherichia coli of a DNA sequence
coding for human growth hormone. Nature 1979; 281: 544_8.
12 Raben MS. Treatment of a pituitary dwarf with human growth
hormone. J Clin Endocrinol Metab 1958; 18: 901_3.
13 Raben MS. Growth hormone. 2. Clinical use of human growth
hormone. N Engl J Med 1962; 266: 82_6.
14 Cuneo RC, Salomon F, McGauley GA, Sonksen PH. The growth
hormone deficiency syndrome in adults. Clin Endocrinol (Oxf)
1992; 37: 387_97.
15 Jorgensen JO, Pedersen SA, Thuesen L, Jorgensen J,
Ingemann-Hansen T, Skakkebaek NE, et al. Beneficial effects of growth
hormone treatment in GH-deficient adults. Lancet 1989; 1: 1221_5.
16 Rosen T, Bengtsson BA. Premature mortality due to
cardiovascular disease in hypopituitarism. Lancet 1990; 336: 285_8.
17 Salomon F, Cuneo RC, Hesp R, Sonksen PH. The effects of
treatment with recombinant human growth hormone on body
composition and metabolism in adults with growth hormone
deficiency. N Engl J Med 1989; 28: 1797_803.
18 Eden S. The secretory pattern of growth hormone. An
experimental study in the rat. Acta Physiol Scand Suppl 1978; 458: 1_54.
19 Jansson JO, Eden S, Isaksson O. Sexual dimorphism in the
control of growth hormone secretion. Endocr Rev 1985; 6: 128_50.
20 Vance ML, Kaiser DL, Evans WS, Furlanetto R, Vale W, Rivier J,
et al. Pulsatile growth hormone secretion in normal man during
a continuous 24-hour infusion of human growth hormone
releasing factor (1-40). Evidence for intermittent somatostatin
secretion. J Clin Invest 1985; 75: 1584_90.
21 Winer LM, Shaw MA, Baumann G. Basal plasma growth hormone
levels in man: new evidence for rhythmicity of growth hormone
secretion. J Clin Endocrinol Metab 1990; 70: 1678_86.
22 van den Berg G, Veldhuis JD, Frolich M, Roelfsema F. An
amplitude-specific divergence in the pulsatile mode of growth
hormone (GH) secretion underlies the gender difference in mean GH
concentrations in men and premenopausal women. J Clin
Endocrinol Metab 1996; 81: 2460_7.
23 Giustina A, Veldhuis JD. Pathophysiology of the neuroregulation
of growth hormone secretion in experimental animals and the
human. Endocr Rev 1998; 19: 717_97.
24 Stolar MW, Baumann G. Secretory patterns of growth hormone
during basal periods in man. Metabolism 1986; 9: 883_8.
25 Massa G, Igout A, Rombauts L, Frankenne F,
Vanderschueren-Lodeweyckx M. Effect of oestrogen status on serum levels of
growth hormone-binding protein and insulin-like growth
factor-I in non-pregnant and pregnant women. Clin Endocrinol (Oxf)
1993; 39: 569_75.
26 Kelly JJ, Rajkovic IA, O'Sullivan AJ, Sernia C, Ho KK. Effects of
different oral oestrogen formulations on insulin-like growth
factor-I, growth hormone and growth hormone binding protein in
post-menopausal women. Clin Endocrinol (Oxf) 1993; 39: 561_7.
27 Dawson-Hughes B, Stern D, Goldman J, Reichlin S. Regulation of
growth hormone and somatomedin-C secretion in
postmenopausal women: effect of physiological estrogen replacement. J
Clin Endocrinol Metab 1986; 2: 424_32.
28 Veldhuis JD, Liem AY, South S, Weltman A, Weltman J, Clemmons
DA, et al. Differential impact of age, sex steroid hormones, and
obesity on basal versus pulsatile growth hormone secretion in
men as assessed in an ultrasensitive chemiluminescence assay. J
Clin Endocrinol Metab 1995; 80: 3209_22.
29 Ho KY, Evans WS, Blizzard RM, Veldhuis JD, Merriam GR, Samojlik
E, et al. Effects of sex and age on the 24-hour profile of growth
hormone secretion in man: importance of endogenous estradiol
concentrations. J Clin Endocrinol Metab 1987; 64: 51_8.
30 Liu L, Merriam GR, Sherins RJ. Chronic sex steroid exposure
increases mean plasma growth hormone concentration and pulse
amplitude in men with isolated hypogonadotropic hypogonadism.
J Clin Endocrinol Metab 1987; 64: 651_6.
31 Iranmanesh A, Lizarralde G, Veldhuis JD. Age and relative
adiposity are specific negative determinants of the frequency and
amplitude of growth hormone (GH) secretory bursts and the
half-life of endogenous GH in healthy men. J Clin Endocrinol Metab
1991; 73: 1081_8.
32 Takahashi Y, Kipnis DM, Daughaday WH. Growth hormone
secretion during sleep. J Clin Invest 1968; 47: 2079_90.
33 Kjaer M, Bangsbo J, Lortie G, Galbo H. Hormonal response to
exercise in humans: influence of hypoxia and physical training.
Am J Physiol 1988; 254: R197_203.
34 Felsing NE, Brasel JA, Cooper DM. Effect of low and high
intensity exercise on circulating growth hormone in men. J Clin
Endocrinol Metab 1992; 75: 157_62.
35 Weltman A, Weltman JY, Schurrer R, Evans WS, Veldhuis JD,
Rogol AD. Endurance training amplifies the pulsatile release of
growth hormone: effects of training intensity. J Appl Physiol
1992; 72: 2188_96.
36 Hartman ML, Veldhuis JD, Johnson ML, Lee MM, Alberti KG,
Samojlik E, et al. Augmented growth hormone (GH) secretory
burst frequency and amplitude mediate enhanced GH secretion
during a two-day fast in normal men. J Clin Endocrinol Metab
1992; 74: 757_65.
37 Masuda A, Shibasaki T, Nakahara M, Imaki T, Kiyosawa Y, Jibiki
K, et al. The effect of glucose on growth hormone
(GH)-releasing hormone-mediated GH secretion in man. J Clin Endocrinol
Metab 1985; 3: 523_6.
38 Imaki T, Shibasaki T, Shizume K, Masuda A, Hotta M, Kiyosawa
Y, et al. The effect of free fatty acids on growth hormone
(GH)-releasing hormone-mediated GH secretion in man. J Clin
Endocrinol Metab 1985; 60: 290_3.
39 Parker ML, Hammond JM, Daughaday WH. The arginine
provocative test: an aid in the diagnosis of hyposomatotropism. J
Clin Endocrinol Metab 1967; 27: 1129_36.
40 Bratusch-Marrain P, Waldhausl W. The influence of amino acids
and somatostatin on prolactin and growth hormone release in
man. Acta Endocrinol (Copenh) 1979; 90: 403_8.
41 Iranmanesh A, Lizarralde G, Johnson ML, Veldhuis JD. Nature of
altered growth hormone secretion in hyperthyroidism. J Clin
Endocrinol Metab 1991; 72: 108_15.
42 Williams T, Maxon H, Thorner MO, Frohman LA. Blunted
growth hormone (GH) response to GH-releasing hormone in
hypothyroidism resolves in the euthyroid state. J Clin Endocrinol
Metab 1985; 61: 454_6.
43 Wehrenberg WB, Janowski BA, Piering AW, Culler F, Jones KL.
Glucocorticoids: potent inhibitors and stimulators of growth
hormone secretion. Endocrinology 1990; 126: 3200_3.
44 Muller EE. Neural control of somatotropic function. Physiol
Rev 1987; 67: 962_1053.
45 Kelijman M, Frohman LA. The role of the cholinergic pathway in
growth hormone feedback. J Clin Endocrinol Metab 1991; 72: 1081_7.
46 Ikkos D, Luft R, Gemzell CA. The effect of human growth
hormone in man. Lancet 1958; 1: 720_1.
47 Bengtsson BA, Brummer RJ, Eden S, Bosaeus I. Body
composition in acromegaly. Clin Endocrinol (Oxf) 1989; 30: 121_30.
48 Brummer RJ, Lonn L, Kvist H, Grangard U, Bengtsson BA,
Sjostrom L. Adipose tissue and muscle volume determination by
computed tomography in acromegaly, before and 1 year after
adenomectomy. Eur J Clin Invest 1993; 23: 199_205.
49 Brumback RA, Barr CE. Myopathy in acromegaly. A case study.
Pathol Res Pract 1983; 1: 41_6.
50 Nagulesparen M, Trickey R, Davies MJ, Jenkins JS. Muscle
changes in acromegaly. BMJ 1976; 2: 914_5.
51 Rooyackers OE, Nair KS. Hormonal regulation of human muscle
protein metabolism. Ann Rev Nutr 1997; 17: 457_85.
52 Cuneo RC, Salomon F, Wiles CM, Hesp R, Sonksen PH. Growth
hormone treatment in growth hormone-deficient adults. I. Effects
on muscle mass and strength. J Appl Physiol 1991; 70: 688_94.
53 Jorgensen JO, Pedersen SA, Thuesen L, Jorgensen J, Moller J, Muller
J, et al. Long-term growth hormone treatment in growth hormone
deficient adults. Acta Endocrinol (Copenh) 1991; 125: 449_53.
54 Beshyah SA, Freemantle C, Shahi M, Anyaoku V, Merson S,
Lynch S, et al. Replacement treatment with biosynthetic human
growth hormone in growth hormone-deficient hypopituitary
adults. Clin Endocrinol (Oxf) 1995; 42: 73_84.
55 Johannsson G, Grimby G, Sunnerhagen KS, Bengtsson BA. Two
years of growth hormone (GH) treatment increase isometric and
isokinetic muscle strength in GH-deficient adults. J Clin Endocrinol
Metab 1997; 82: 2877_84.
56 Wallymahmed ME, Foy P, Shaw D, Hutcheon R, Edwards RH,
MacFarlane IA. Quality of life, body composition and muscle
strength in adult growth hormone deficiency: the influence of
growth hormone replacement therapy for up to 3 years. Clin
Endocrinol (Oxf) 1997; 47: 439_46.
57 Sartorio A, Narici MV. Growth hormone (GH) treatment in
GH-deficient adults: effects on muscle size, strength and neural
activation. Clin Physiol 1994; 14: 527_37.
58 Cuneo RC, Salomon F, Wiles CM, Sonksen PH. Skeletal muscle
performance in adults with growth hormone deficiency. Horm
Res 1990; 33 (Suppl 4): 55_60.
59 Cuneo RC, Salomon F, Wiles CM, Hesp R, Sonksen PH. Growth
hormone treatment in growth hormone-deficient adults. II. Effects
on exercise performance. J Appl Physiol 1991; 70: 695_700.
60 Whitehead HM, Boreham C, McIlrath EM, Sheridan B, Kennedy
L, Atkinson AB, et al. Growth hormone treatment of adults with
growth hormone deficiency: results of a 13-month placebo
controlled cross-over study. Clin Endocrinol (Oxf) 1992; 36: 45_52.
61 Christiansen JS, Jorgensen JO, Pedersen SA, Muller J, Jorgensen
J, Moller J, et al. GH-replacement therapy in adults. Horm Res
1991; 36 (Suppl 1): 66_72.
62 Johannsson G, Bengtsson BA, Andersson B, Isgaard J, Caidahl K.
Long-term cardiovascular effects of growth hormone treatment
in GH-deficient adults. Preliminary data in a small group of
patients. Clin Endocrinol (Oxf) 1996; 45: 305_14.
63 Rutherford OM, Jones DA, Round JM, Preece MA. Changes in
skeletal muscle after discontinuation of growth hormone
treatment in young adults with hypopituitarism. Acta Paediatr Scand
Suppl 1989; 356: 61_3; discussion 64, 73_4.
64 Degerblad M, Almkvist O, Grunditz R, Hall K, Kaijser L, Knutsson
E, et al. Physical and psychological capabilities during
substitution therapy with recombinant growth hormone in adults with
growth hormone deficiency. Acta Endocrinol (Copenh) 1990;
123: 185_93.
65 Ayling CM, Moreland BH, Zanelli JM, Schulster D. Human growth
hormone treatment of hypophysectomized rats increases the
proportion of type-1 fibres in skeletal muscle. J Endocrinol 1989;
123: 429_35.
66 Cuneo RC, Salomon F, Wiles CM, Round JM, Jones D, Hesp R,
et al. Histology of skeletal muscle in adults with GH deficiency:
comparison with normal muscle and response to GH treatment.
Horm Res 1992; 37: 23_8.
67 Whitehead HM, Gilliland JS, Allen IV, Hadden DR. Growth
hormone treatment in adults with growth hormone deficiency:
effect on muscle fibre size and proportions. Acta Paediatr Scand
Suppl 1989; 356: 65_7.
68 Raben MS, Hollenberg CH. Effect of growth hormone on plasma
fatty acids. J Clin Invest 1959; 38: 484_8.
69 Rosen T, Bosaeus I, Tolli J, Lindstedt G, Bengtsson BA.
Increased body fat mass and decreased extracellular fluid volume in
adults with growth hormone deficiency. Clin Endocrinol (Oxf)
1993; 38: 63_71.
70 De Boer H, Blok GJ, Voerman HJ, De Vries PM, van der Veen EA.
Body composition in adult growth hormone-deficient men,
assessed by anthropometry and bioimpedance analysis. J Clin
Endocrinol Metab 1992; 75: 833_7.
71 Lonn L, Johansson G, Sjostrom L, Kvist H, Oden A, Bengtsson
BA. Body composition and tissue distributions in growth
hormone deficient adults before and after growth hormone treatment.
Obes Res 1996; 4: 45_54.
72 Ho KY, Veldhuis JD, Johnson ML, Furlanetto R, Evans WS,
Alberti KG, et al. Fasting enhances growth hormone secretion
and amplifies the complex rhythms of growth hormone
secretion in man. J Clin Invest 1988; 81: 968_75.
73 Copeland KC, Nair KS. Acute growth hormone effects on amino acid
and lipid metabolism. J Clin Endocrinol Metab 1994; 78: 1040_7.
74 Dietz J, Schwartz J. Growth hormone alters lipolysis and
hormone-sensitive lipase activity in 3T3-F442A adipocytes.
Metabolism 1991; 40: 800_6.
75 Whitney JE, Bennett LL, Li CH. Reduction of urinary sodium
and potassium produced by hypophyseal growth hormone in
normal female rats. Proc Soc Exp Biol Med 1952; 79: 584_7.
76 Johannsson G, Sverrisdottir YB, Ellegard L, Lundberg PA, Herlitz
H. GH increases extracellular volume by stimulating sodium
reabsorption in the distal nephron and preventing pressure natriuresis.
J Clin Endocrinol Metab 2002; 87: 1743_9.
77 Moller J, Moller N, Frandsen E, Wolthers T, Jorgensen JO,
Christiansen JS. Blockade of the renin-angiotensin-aldosterone
system prevents growth hormone-induced fluid retention in
humans. Am J Physiol 1997; 272: E803_8.
78 Moller J, Jorgensen JO, Moller N, Hansen KW, Pedersen EB,
Christiansen JS. Expansion of extracellular volume and suppression
of atrial natriuretic peptide after growth hormone administration in
normal man. J Clin Endocrinol Metab 1991; 72: 768_72.
79 Boger RH, Skamira C, Bode-Boger SM, Brabant G, von zur Muhlen
A, Frolich JC. Nitric oxide may mediate the hemodynamic
effects of recombinant growth hormone in patients with acquired
growth hormone deficiency. A double-blind, placebo-controlled
study. J Clin Invest 1996; 98: 2706_13.
80 Bengtsson BA, Brummer RJ, Eden S, Bosaeus I, Lindstedt G.
Body composition in acromegaly: the effect of treatment. Clin
Endocrinol (Oxf) 1989; 31: 481_90.
81 Davies DL, Beastall GH, Connell JM, Fraser R, McCruden D,
Teasdale GM. Body composition, blood pressure and the
renin-angiotensin system in acromegaly before and after treatment. J
Hypertens Suppl 1985; 3: S413_5.
82 Maor G, Hochberg Z, von der Mark K, Heinegard D, Silbermann
M. Human growth hormone enhances chondrogenesis and
osteogenesis in a tissue culture system of chondroprogenitor cells.
Endocrinology 1989; 125: 1239_45.
83 Nishiyama K, Sugimoto T, Kaji H, Kanatani M, Kobayashi T,
Chihara K. Stimulatory effect of growth hormone on bone
resorption and osteoclast differentiation. Endocrinology 1996;
137: 35_41.
84 Slootweg MC, van Buul-Offers SC, Herrmann-Erlee MP, van der
Meer JM, Duursma SA. Growth hormone is mitogenic for fetal
mouse osteoblasts but not for undifferentiated bone cells. J
Endocrinol 1988; 116: R11_3.
85 Kann P, Piepkorn B, Schehler B, Andreas J, Lotz J, Prellwitz W,
et al. Effect of long-term treatment with GH on bone metabolism,
bone mineral density and bone elasticity in GH-deficient adults.
Clin Endocrinol (Oxf) 1998; 48: 561_8.
86 Ohlsson C, Bengtsson BA, Isaksson OG, Andreassen TT, Slootweg
MC. Growth hormone and bone. Endocr Rev 1998; 19: 55_79.
87 Schlemmer A, Johansen JS, Pedersen SA, Jorgensen JO, Hassager
C, Christiansen C. The effect of growth hormone (GH) therapy
on urinary pyridinoline cross-links in GH-deficient adults. Clin
Endocrinol (Oxf) 1991; 35: 471_6.
88 Amato G, Carella C, Fazio S, La Montagna G, Cittadini A, Sabatini
D, et al. Body composition, bone metabolism, and heart
structure and function in growth hormone (GH)-deficient adults
before and after GH replacement therapy at low doses. J Clin
Endocrinol Metab 1993; 77: 1671_6.
89 Degerblad M, Bengtsson BA, Bramnert M, Johnell O, Manhem
P, Rosen T, et al. Reduced bone mineral density in adults with
growth hormone (GH) deficiency: increased bone turnover
during 12 months of GH substitution therapy. Eur J Endocrinol
1995; 133: 180_8.
90 Vandeweghe M, Taelman P, Kaufman JM. Short and long-term
effects of growth hormone treatment on bone turnover and bone
mineral content in adult growth hormone-deficient males. Clin
Endocrinol (Oxf) 1993; 39: 409_15.
91 Johannsson G, Rosen T, Bosaeus I, Sjostrom L, Bengtsson BA.
Two years of growth hormone (GH) treatment increases bone
mineral content and density in hypopituitary patients with
adult-onset GH deficiency. J Clin Endocrinol Metab 1996; 81: 2865_73.
92 McHugh CM, Park RT, Sonksen PH, Holt RI. Challenges in
detecting the abuse of growth hormone in sport. Clin Chem
2005; 51: 1587_93.
93 Bidlingmaier M, Wu Z, Strasburger CJ. Test method: GH. Baillieres
Best Pract Res Clin Endocrinol Metab 2000; 14: 99_109.
94 Wu Z, Bidlingmaier M, Dall R, Strasburger CJ. Detection of
doping with human growth hormone. Lancet 1999; 353: 895.
95 Wallace JD, Cuneo RC, Bidlingmaier M, Lundberg PA, Carlsson
L, Boguszewski CL, et al. Changes in non-22-kilodalton (kDa)
isoforms of growth hormone (GH) after administration of
22-kDa recombinant human GH in trained adult males. J Clin
Endocrinol Metab 2001; 86: 1731_7.
96 Wallace JD, Cuneo RC, Bidlingmaier M, Lundberg PA, Carlsson
L, Boguszewski CL, et al. The response of molecular isoforms of
growth hormone to acute exercise in trained adult males. J Clin
Endocrinol Metab 2001; 1: 200_6.
97 Wallace JD, Cuneo RC, Baxter R, Orskov H, Keay N, Pentecost
C, et al. Responses of the growth hormone (GH) and insulin-like
growth factor axis to exercise, GH administration, and GH
withdrawal in trained adult males: a potential test for GH abuse in
sport. J Clin Endocrinol Metab 1999; 84: 3591_601.
98 Wallace JD, Cuneo RC, Lundberg PA, Rosen T, Jorgensen JO,
Longobardi S, et al. Responses of markers of bone and collagen
turnover to exercise, growth hormone (GH) administration, and
GH withdrawal in trained adult males. J Clin Endocrinol Metab
2000; 85: 124_33.
99 Eliakim A, Brasel JA, Mohan S, Barstow TJ, Berman N, Cooper
DM. Physical fitness, endurance training, and the growth
hormone-insulin-like growth factor I system in adolescent females.
J Clin Endocrinol Metab 1996; 81: 3986_92.
100 Eliakim A, Brasel JA, Barstow TJ, Mohan S, Cooper DM. Peak
oxygen uptake, muscle volume, and the growth
hormone-insulin-like growth factor-I axis in adolescent males. Med Sci Sports
Exerc 1998; 30: 512_7.
101 Kelly PJ, Eisman JA, Stuart MC, Pocock NA, Sambrook PN,
Gwinn TH. Somatomedin-C, physical fitness, and bone density. J
Clin Endocrinol Metab 1990; 70: 718_23.
102 Poehlman ET, Copeland KC. Influence of physical activity on
insulin-like growth factor-I in healthy younger and older men. J
Clin Endocrinol Metab 1990; 71: 1468_73.
103 Kraemer WJ, Gordon SE, Fleck SJ, Marchitelli LJ, Mello R,
Dziados JE, et al. Endogenous anabolic hormonal and growth
factor responses to heavy resistance exercise in males and females.
Int J Sports Med 1991; 12: 228_35.
104 Kristoffersson A, Hultdin J, Holmlund I, Thorsen K, Lorentzon
R. Effects of short-term maximal work on plasma calcium,
parathyroid hormone, osteocalcin and biochemical markers of
collagen metabolism. Int J Sports Med 1995; 16: 145_9.
105 Welsh L, Rutherford OM, James I, Crowley C, Comer M, Wolman
R. The acute effects of exercise on bone turnover. Int J Sports
Med 1997; 18: 247_51.
106 Virtanen P, Viitasalo JT, Vuori J, Vaananen K, Takala TE. Effect
of concentric exercise on serum muscle and collagen markers. J
Appl Physiol 1993; 75: 1272_7.
107 Nishiyama S, Tomoeda S, Ohta T, Higuchi A, Matsuda I.
Differences in basal and postexercise osteocalcin levels in athletic and
nonathletic humans. Calcif Tissue Int 1988; 43: 150_4.
108 Salvesen H, Johansson AG, Foxdal P, Wide L, Piehl-Aulin K,
Ljunghall S. Intact serum parathyroid hormone levels increase
during running exercise in well-trained men. Calcif Tissue Int
1994; 54: 256_61.
109 Weitzman ED, deGraaf AS, Sassin JF, Hansen T, Godtlibsen OB,
Perlow M, et al. Seasonal patterns of sleep stages and secretion
of cortisol and growth hormone during 24 hour periods in
northern Norway. Acta Endocrinol (Copenh) 1975; 78: 65_76.
110 Bellastella A, Criscuolo T, Mango A, Perrone L, Sinisi AA,
Faggiano M. Circannual rhythms of plasma growth hormone,
thyrotropin and thyroid hormones in prepuberty. Clin Endocrinol
(Oxf) 1984; 20: 531_7.
111 Chapuy MC, Schott AM, Garnero P, Hans D, Delmas PD, Meunier
PJ. Healthy elderly French women living at home have secondary
hyperparathyroidism and high bone turnover in winter. EPIDOS
Study Group. J Clin Endocrinol Metab 1996; 81: 1129_33.
112 Douglas AS, Miller MH, Reid DM, Hutchison JD, Porter RW,
Robins SP. Seasonal differences in biochemical parameters of
bone remodelling. J Clin Path 1996; 49: 284_9.
113 Hyldstrup L, McNair P, Jensen GF, Transbol I. Seasonal
variations in indices of bone formation precede appropriate bone
mineral changes in normal men. Bone 1986; 7: 167_70.
114 Overgaard K, Nilas L, Johansen JS, Christiansen C. Lack of
seasonal variation in bone mass and biochemical estimates of bone
turnover. Bone 1988; 9: 285_8.
115 Storm D, Eslin R, Porter ES, Musgrave K, Vereault D, Patton C,
et al. Calcium supplementation prevents seasonal bone loss and
changes in biochemical markers of bone turnover in elderly New
England women: a randomized placebo-controlled trial. J Clin
Endocrinol Metab 1998; 83: 3817_25.
116 Thomsen K, Eriksen EF, Jorgensen JC, Charles P, Mosekilde L.
Seasonal variation of serum bone GLA protein. Scand J Clin Lab
Invest 1989; 49: 605_11.
117 Vanderschueren D, Gevers G, Dequeker J, Geusens P, Nijs J, Devos
P, et al. Seasonal variation in bone metabolism in young healthy
subjects. Calcif Tissue Int 1991; 49: 84_9.
118 Woitge HW, Scheidt-Nave C, Kissling C, Leidig-Bruckner G,
Meyer K, Grauer A, et al. Seasonal variation of biochemical
indexes of bone turnover: results of a population-based study. J
Clin Endocrinol Metab 1998; 83: 68_75.
119 Bengtsson BA, Eden S, Lonn L, Kvist H, Stokland A, Lindstedt
G, et al. Treatment of adults with growth hormone (GH)
deficiency with recombinant human GH. J Clin Endocrinol Metab
1993; 76: 309_17.
120 Bowes SB, Umpleby M, Cummings MH, Jackson NC, Carroll PV,
Lowy C, et al. The effect of recombinant human growth
hormone on glucose and leucine metabolism in Cushing's syndrome.
J Clin Endocrinol Metab 1997; 82: 243_6.
121 Inoue Y, Copeland EM, Souba WW. Growth hormone enhances
amino acid uptake by the human small intestine. Ann Surg 1994;
219: 715_22.
122 Umpleby AM, Boroujerdi MA, Brown PM, Carson ER, Sonksen PH.
The effect of metabolic control on leucine metabolism in type 1
(insulin-dependent) diabetic patients. Diabetologia 1986; 29: 131_41.
123 Tessari P, Trevisan R, Inchiostro S, Biolo G, Nosadini R, De
Kreutzenberg SV, et al. Dose-response curves of effects of insulin
on leucine kinetics in humans. Am J Physiol 1986; 251: E334_42.
124 Russell-Jones DL, Umpleby AM, Hennessy TR, Bowes SB,
Shojaee-Moradie F, Hopkins KD, et al. Use of a leucine clamp to
demonstrate that IGF-I actively stimulates protein synthesis in
normal humans. Am J Physiol 1994; 267: E591_8.
125 Yarasheski KE, Campbell JA, Smith K, Rennie MJ, Holloszy JO,
Bier DM. Effect of growth hormone and resistance exercise on
muscle growth in young men. Am J Physiol 1992; 262: E261_7.
126 Deyssig R, Frisch H, Blum WF, Waldhor T. Effect of growth
hormone treatment on hormonal parameters, body composition and
strength in athletes. Acta Endocrinol (Copenh) 1993; 128: 313_8.
127 Crist DM, Peake GT, Egan PA, Waters DL. Body composition
response to exogenous GH during training in highly conditioned
adults. J Applied Physiol 1988; 65: 579_84.
128 Yarasheski KE, Zachweija JJ, Angelopoulos TJ, Bier DM.
Short-term growth hormone treatment does not increase muscle
protein synthesis in experienced weight lifters. J Applied Physiol
1993; 74: 3073_6.
129 Healy ML, Gibney J, Russell-Jones DL, Pentecost C, Croos P,
Sonksen PH, et al. High dose growth hormone exerts an anabolic
effect at rest and during exercise in endurance-trained athletes. J
Clin Endocrinol Metab 2003; 88: 5221_6.
130 Berggren A, Ehrnborg C, Rosen T, Ellegard L, Bengtsson BA,
Caidahl K. Short-term administration of supraphysiological
recombinant human growth hormone (GH) does not increase
maximum endurance exercise capacity in healthy, active young men
and women with normal GH-insulin-like growth factor I axes. J
Clin Endocrinol Metab 2005; 6: 3268_73.
131 Ehrnborg C, Ellegard L, Bosaeus I, Bengtsson BA, Rosen T.
Supraphysiological growth hormone: less fat, more extracellular
fluid but uncertain effects on muscles in healthy, active young
adults. Clin Endocrinol (Oxf) 2005; 62: 449_57.
132 Yarasheski KE, Zachwieja JJ, Campbell JA, Bier DM. Effect of
growth hormone and resistance exercise on muscle growth and
strength in older men. Am J Physiol 1995; 268: E268_76.
133 Taaffe DR, Jin IH, Vu TH, Hoffman AR, Marcus R. Lack of effect of
recombinant human growth hormone (GH) on muscle morphology
and GH-insulin-like growth factor expression in resistance-trained
elderly men. J Clin Endocrinol Metab 1996; 81: 421_5.
134 Taaffe DR, Pruitt L, Reim J, Hintz RL, Butterfield G, Hoffman
AR, et al. Effect of recombinant human growth hormone on the
muscle strength response to resistance exercise in elderly men. J
Clin Endocrinol Metab 1994; 79: 1361_6.
135 Cowart VS. Human growth hormone: the latest ergogenic aid?
Phys Sports Med 1988; 16: 175_85.
136 Frisch H. Growth hormone and body composition in athletes. J
Endocrinol Invest 1999; 22: 106_9.
137 Rennie MJ. Claims for the anabolic effects of growth hormone: a case
of the emperor's new clothes? Br J Sports Med 2003; 37: 100_5.
138 Weber MM. Effects of growth hormone on skeletal muscle. Horm
Res 2002; 58 (Suppl 3): 43_8.
139 Lange KH, Isaksson F, Rasmussen MH, Juul A, Bulow J, Kjaer M.
GH administration and discontinuation in healthy elderly men:
effects on body composition, GH-related serum markers, resting
heart rate and resting oxygen uptake. Clin Endocrinol (Oxf)
2001; 55: 77_86.
140 Cittadini A, Berggren A, Longobardi S, Ehrnborg C, Napoli R,
Rosen T, et al. Supraphysiological doses of GH induce rapid
changes in cardiac morphology and function. J Clin Endocrinol
Metab 2002; 87: 1654_9.
141 Colao A, Ferone D, Marzullo P, Lombardi G. Systemic
complications of acromegaly: epidemiology, pathogenesis, and management.
Endocr Rev 2004; 25: 102_52.
142 Deyssig R, Frisch H. Self-administration of cadaveric growth
hormone in power athletes. Lancet 1993; 341: 768_9.
143 Doessing S, Kjaer M. Growth hormone and connective tissue in
exercise. Scand J Med Sci Sports 2005; 15: 202_10.
144 Rosen T. Supraphysiological doses of growth hormone: effects
on muscles and collagen in healthy active young adults. Horm
Res 2006; 66: 98_104.
145 Colao A, Marzullo P, Vallone G, Marino V, Annecchino M, Ferone
D, et al. Reversibility of joint thickening in acromegalic patients: an
ultrasonography study. J Clin Endocrinol Metab 1998; 83: 2121_5.
146 Colao A, Marzullo P, Vallone G, Giaccio A, Ferone D, Rossi E,
et al. Ultrasonographic evidence of joint thickening reversibility in
acromegalic patients treated with lanreotide for 12 months. Clin
Endocrinol (Oxf) 1999; 51: 611_8.
147 Colao A, Di Somma C, Pivonello R, Loche S, Aimaretti G, Cerbone
G, et al. Bone loss is correlated to the severity of growth
hormone deficiency in adult patients with hypopituitarism. J Clin
Endocrinol Metab 1999; 84: 1919_24.
148 Baroncelli GI, Bertelloni S, Ceccarelli C, Cupelli D, Saggese G.
Dynamics of bone turnover in children with GH deficiency treated
with GH until final height. Eur J Endocrinol 2000; 142: 549_56.
149 Lange M, Thulesen J, Feldt-Rasmussen U, Skakkebaek NE, Vahl
N, Jorgensen JO, et al. Skin morphological changes in growth
hormone deficiency and acromegaly. Eur J Endocrinol 2001;
145: 147_53.
150 Scarpa R, De Brasi D, Pivonello R, Marzullo P, Manguso F,
Sodano A, et al. Acromegalic axial arthropathy: a clinical
case-control study. J Clin Endocrinol Metab 2004; 89: 598_603.
151 Longobardi S, Keay N, Ehrnborg C, Cittadini A, Rosen T, Dall R,
et al. Growth hormone (GH) effects on bone and collagen
turnover in healthy adults and its potential as a marker of GH abuse
in sports: a double blind, placebo-controlled study. The GH-2000
Study Group. J Clin Endocrinol Metab 2000; 85: 1505_12.
152 Kurtz CA, Loebig TG, Anderson DD, DeMeo PJ, Campbell PG.
Insulin-like growth factor I accelerates functional recovery from Achilles
tendon injury in a rat model. Am J Sports Med 1999; 27: 363_9.
153 Verducci T, Yeager D, Dohrmann G, Llosa LF, Munson L.
Totally juiced. Sports Illustrated 2002; 96: 34_7.
154 Rigamonti AE, Cella SG, Marazzi N, Di Luigi L, Sartorio A,
Muller EE. Growth hormone abuse: methods of detection. Trends
Endocrinol Metab 2005; 16: 160_6.
155 Saugy M, Robinson N, Saudan C, Baume N, Avois L, Mangin P.
Human growth hormone doping in sport. Br J Sports Med 2006;
40 (Suppl 1): i35_9.
156 Boguszewski CL, Hynsjo L, Johannsson G, Bengtsson BA,
Carlsson LM. 22-kD growth hormone exclusion assay: a new
approach to measurement of non-22-kD growth hormone
isoforms in human blood. Eur J Endocrinol 1996; 135: 573_82.
157 Dall R, Longobardi S, Ehrnborg C, Keay N, Rosen T, Jorgensen
JO, et al. The effect of four weeks of supraphysiological growth
hormone administration on the insulin-like growth factor axis in
women and men. GH-2000 Study Group. J Clin Endocrinol Metab
2000; 85: 4193_200.
158 Giannoulis MG, Boroujerdi MA, Powrie J, Dall R, Napoli R,
Ehrnborg C, et al. Gender differences in growth hormone
response to exercise before and after rhGH administration and the
effect of rhGH on the hormone profile of fit normal adults. Clin
Endocrinol (Oxf) 2005; 62: 315_22.
159 Healy ML, Dall R, Gibney J, Bassett E, Ehrnborg C, Pentecost C,
et al. Toward the development of a test for growth hormone
(GH) abuse: a study of extreme physiological ranges of
GH-dependent markers in 813 elite athletes in the postcompetition
setting. J Clin Endocrinol Metab 2005; 90: 641_9.
160 Powrie JK, Bassett EE, Rosen T, Jorgensen JO, Napoli R, Sacca
L, et al. Detection of growth hormone abuse in sport. Growth
Horm IGF Res 2007; 17: 220_6.
161 Erotokritou-Mulligan I, Bassett EE, Kniess A, Sonksen PH, Holt
RI. Validation of the growth hormone (GH)-dependent marker
method of detecting GH abuse in sport through the use of
independent data sets. Growth Horm IGF Res 2007; 17: 416_23.
|